Acuta Capital Partners LLC Buys New Position in Ascendis Pharma A/S (NASDAQ:ASND)

Acuta Capital Partners LLC purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,000 shares of the biotechnology company’s stock, valued at approximately $3,136,000. Ascendis Pharma A/S makes up approximately 2.5% of Acuta Capital Partners LLC’s holdings, making the stock its 17th largest holding.

Other institutional investors have also recently made changes to their positions in the company. Avoro Capital Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after acquiring an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP raised its position in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after purchasing an additional 155,971 shares during the last quarter. Fred Alger Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock worth $41,879,000 after purchasing an additional 120,952 shares in the last quarter. Finally, Tri Locum Partners LP raised its holdings in shares of Ascendis Pharma A/S by 102.1% during the 2nd quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after buying an additional 115,092 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $136.32 on Thursday. Ascendis Pharma A/S has a fifty-two week low of $90.13 and a fifty-two week high of $161.00. The company has a market capitalization of $8.27 billion, a price-to-earnings ratio of -16.58 and a beta of 0.66. The business’s 50 day moving average price is $132.80 and its two-hundred day moving average price is $132.18.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Sell-side analysts forecast that Ascendis Pharma A/S will post -7.45 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Stifel Nicolaus upped their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Evercore ISI boosted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Wedbush reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Bank of America raised their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.